Table 3. Associations with progression-free survival and clinicopathological characteristics in TCGA patients using Cox regression.

Characteristics	Total(N)	HR (95% CI), univariate analysis	P value, univariate analysis	HR (95% CI), multivariate analysis	P value, multivariate analysis
T stage (T3 & T4 vs. T2)	488	3.716 (2.100–6.575)	<0.001	1.471 (0.692–3.124)	0.316
N stage (N1 vs. N0)	422	1.854 (1.137–3.026)	0.013	0.726 (0.411–1.285)	0.272
M stage (M1 vs. M0)	456	3.648 (0.505–26.354)	0.200
Gleason score (8 & 9 & 10 vs. 6 & 7)	495	4.603 (2.909–7.284)	<0.001	3.120 (1.677–5.805)	<0.001
Primary therapy outcome (PD & SD & PR vs. CR)	434	6.793 (4.430–10.416)	<0.001	3.657 (2.085–6.414)	<0.001
Residual tumor (R1 & R2 vs. R0)	465	2.320 (1.533–3.510)	<0.001	1.028 (0.601–1.757)	0.921
PSA (ng/mL) (≥4 vs. <4)	438	4.246 (2.119–8.510)	<0.001	1.437 (0.630–3.278)	0.389
Age (>60 vs. ≤60)	495	1.274 (0.843–1.923)	0.250
Race (White vs. Asian & Black or African American)	480	1.309 (0.726–2.360)	0.371
Zone of origin (overlapping/multiple zones vs. peripheral zone)	262	1.293 (0.794–2.108)	0.302
TP53 status (Mut vs. WT)	492	2.086 (1.258–3.461)	0.004	0.956 (0.553-1.655)	0.874
SNHG9 (high vs. low)	495	1.974 (1.290–3.020)	0.002	1.776 (1.067-2.955)	0.027

CR, complete response; PD, progressive disease; SD, stable disease; PR, partial response; PSA, prostate specific antigen.